Greater understanding of the tumor microenvironment of nasopharyngeal carcinoma (NPC) has led to the introduction of immunotherapy into the NPC treatment landscape. Incorporating immunotherapy has changed the current standard of care in the treatment of recurrent and metastatic NPC. Robert Ferris, MD, explores clinical trial data leading to approval of PD-1 inhibitors both as monotherapy and in combination with chemotherapy. He also delves into the significance of biomarkers that may influence prognosis and management of patients with NPC, as well as managing toxicity related to PD-1 inhibitors.

Please visit our related course, Interprofessional Care of Patients with Nasopharyngeal Cancer, by clicking here.

Presenting Faculty

• 

  Robert Ferris, MD, PhD

  Associate Senior Vice Chancellor for Cancer Research, Health Sciences
  Hillman Professor of Oncology
  Professor of Otolaryngology, of Immunology, and of Radiation Oncology, School of Medicine
  Director, UPMC Hillman Cancer Center
  Pittsburgh, Pennsylvania